SCHEMBL14416652

SCHEMBL14416652

CCCn1c(-c2ccccc2)nc(F)c1CN(Cc1ccc2c(c1)OCO2)CC1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.49
CTSL P07711 3/20 0.41
KDM4E B2RXH2 1/20 0.39
GFER P55789 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
F2R P25116 5/20 0.37
TSHR P16473 3/20 0.35
ALDH1A1 P00352 3/20 0.35
NPSR1 Q6W5P4 3/20 0.35
USP2 O75604 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649999 0.95 C5AR1 (0.56) C5AR1CTSLSMN1; SMN2TDP1PPARG
SCHEMBL649149 0.86 C5AR1 (0.64) C5AR1CTSLKDM4ESMN1; SMN2TDP1
SCHEMBL650388 0.84 C5AR1 (0.65) C5AR1CTSLKDM4EGFERSMN1; SMN2
SCHEMBL1912864 0.83 C5AR1 (0.63) C5AR1KDM4EGFERSMN1; SMN2TDP1
SCHEMBL649490 0.82 C5AR1 (0.62) C5AR1KDM4EGFERSMN1; SMN2TDP1
SCHEMBL5135945 0.81 C5AR1 (0.57) C5AR1CTSLKDM4ESMN1; SMN2TDP1
SCHEMBL652877 0.80 C5AR1 (0.66) C5AR1KDM4EGFERSMN1; SMN2TDP1
SCHEMBL651679 0.80 C5AR1 (0.58) C5AR1KDM4EGFERSMN1; SMN2TDP1
SCHEMBL648390 0.79 C5AR1 (0.54) C5AR1KDM4ESMN1; SMN2TDP1PPARG
SCHEMBL651099 0.79 C5AR1 (0.58) C5AR1SMN1; SMN2TDP1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators C3AR1, C5AR1, C5AR2 C5AR1 2/4885CTSL 3062/4885KDM4E 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.